{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:34:13Z","timestamp":1740126853039,"version":"3.37.3"},"reference-count":82,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Migraine significantly impacts individuals from all walks of life and from all around the globe. Chronic or high-frequency episodic migraine has similar disability and burden on the healthcare system and can be challenging to manage. The focus of this article is to provide an outline of the available pharmacological and nonpharmacological evidence-based strategies that clinicians can employ to build a \u201ctoolbox\u201d for their patients.<\/jats:p>","DOI":"10.1055\/a-1933-4366","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T23:04:10Z","timestamp":1661900650000},"page":"503-511","source":"Crossref","is-referenced-by-count":0,"title":["Preventive Treatment of Migraine"],"prefix":"10.1055","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3912-3927","authenticated-orcid":false,"given":"Candice M.","family":"Todd","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire H.","family":"Sandoe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Lay","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"issue":"07","key":"ref1","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/033310240102100708","article-title":"Epidemiology of headache","volume":"21","author":"B K Rasmussen","year":"2001","journal-title":"Cephalalgia"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/head.12774","article-title":"Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study","volume":"56","author":"D W Dodick","year":"2016","journal-title":"Headache"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/head.13966","article-title":"Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study","author":"D C Buse","year":"2020","journal-title":"Headache"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/head.12878","article-title":"A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache-related disability","volume":"56","author":"R B Lipton","year":"2016","journal-title":"Headache"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/head.14154","article-title":"Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency","volume":"61","author":"R Ishii","year":"2021","journal-title":"Headache"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"J Ailani","year":"2021","journal-title":"Headache"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis","volume":"37","author":"Z Hepp","year":"2017","journal-title":"Cephalalgia"},{"issue":"17","key":"ref8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"S D Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","article-title":"Migraine \u2013 current understanding and treatment","volume":"346","author":"P J Goadsby","year":"2002","journal-title":"N Engl J Med"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.288.3.351","article-title":"Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction","volume":"288","author":"D T Ko","year":"2002","journal-title":"JAMA"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1526-4610.1991.hed3105333.x","article-title":"Propranolol in the management of recurrent migraine: a meta-analytic review","volume":"31","author":"K A Holroyd","year":"1991","journal-title":"Headache"},{"issue":"18","key":"ref12","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/jama.1984.03350180030025","article-title":"Migraine prevention with timolol. A double-blind crossover study","volume":"252","author":"S Stellar","year":"1984","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1017\/CBO9781139194464.099","volume-title":"Essential Pain Pharmacology: The Prescriber's Guide. Timolol","author":"H S Smith","year":"2012"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1526-4610.1986.hed2610490.x","article-title":"Nadolol and propranolol in migraine management","volume":"26","author":"B Olerud","year":"1986","journal-title":"Headache"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clinthera.2009.03.020","article-title":"Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs","volume":"31","author":"D W Dodick","year":"2009","journal-title":"Clin Ther"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","author":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"ref17","first-page":"l6213","article-title":"Anticholinergic drugs and risk of dementia: case-control study","volume":"367","author":"K Richardson","year":"2019","journal-title":"BMJ"},{"issue":"S 03","key":"ref18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/head.13375","article-title":"Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018","volume":"58","author":"E Loder","year":"2018","journal-title":"Headache"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","article-title":"The efficacy and safety of venlafaxine in the prophylaxis of migraine","volume":"45","author":"S N Ozyalcin","year":"2005","journal-title":"Headache"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clineuro.2004.03.004","article-title":"Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study","volume":"107","author":"S Bulut","year":"2004","journal-title":"Clin Neurol Neurosurg"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11940-019-0557-2","article-title":"Antidepressants for preventive treatment of migraine","volume":"21","author":"R Burch","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"01","key":"ref22","first-page":"17","article-title":"Migraine headache prophylaxis","volume":"99","author":"H Ha","year":"2019","journal-title":"Am Fam Physician"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"S D Silberstein","year":"2007","journal-title":"Headache"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"H C Diener","year":"2007","journal-title":"Cephalalgia"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1046\/j.1468-2982.2003.00592.x","article-title":"Topiramate in the treatment of chronic migraine","volume":"23","author":"M Silvestrini","year":"2003","journal-title":"Cephalalgia"},{"key":"ref26","first-page":"973","article-title":"Preventive migraine treatment","volume":"21","author":"S D Silberstein","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.earlhumdev.2005.11.001","article-title":"Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists","volume":"82","author":"A Quan","year":"2006","journal-title":"Early Hum Dev"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1468-1331.2007.01764.x","article-title":"Efficacy of lisinopril in migraine prophylaxis \u2013 an open label study","volume":"14","author":"S Schuh-Hofer","year":"2007","journal-title":"Eur J Neurol"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","article-title":"Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review","volume":"60","author":"M Bullo","year":"2012","journal-title":"Hypertension"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00023210-200822100-00007","article-title":"Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study","volume":"22","author":"M M Tuchman","year":"2008","journal-title":"CNS Drugs"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/head.12978","article-title":"Menstrual migraine and treatment options: review","volume":"57","author":"K Maasumi","year":"2017","journal-title":"Headache"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/03331024211034508","article-title":"BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm","volume":"42","author":"D Martinelli","year":"2022","journal-title":"Cephalalgia"},{"issue":"07","key":"ref33","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/head.13823","article-title":"Modifications to the PREEMPT protocol for onabotulinumtoxinA injections for chronic migraine in clinical practice","volume":"60","author":"O Begasse de Dhaem","year":"2020","journal-title":"Headache"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(21)00468-3","article-title":"CGRP-targeted drugs for migraine: still many uncertainties","volume":"21","author":"H C Diener","year":"2022","journal-title":"Lancet Neurol"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/head.14266","article-title":"Erenumab dosage for migraine prevention: an evidence-based narrative review with recommendations","volume":"62","author":"S J Tepper","year":"2022","journal-title":"Headache"},{"issue":"01","key":"ref36","first-page":"211","article-title":"Temporal response patterns to erenumab in patients with chronic migraine","volume":"39","author":"S J Tepper","year":"2019","journal-title":"Cephalalgia"},{"issue":"09","key":"ref37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/head.14194","article-title":"Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study","volume":"61","author":"P Barbanti","year":"2021","journal-title":"Headache"},{"issue":"09","key":"ref38","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/head.14208","article-title":"Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data","volume":"61","author":"D W Dodick","year":"2021","journal-title":"Headache"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-021-00469-8","article-title":"New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database","volume":"35","author":"M Sessa","year":"2021","journal-title":"BioDrugs"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s10194-021-01358-9","article-title":"Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States","volume":"22","author":"P McAllister","year":"2021","journal-title":"J Headache Pain"},{"issue":"22","key":"ref41","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"S D Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2147\/JPR.S222604","article-title":"Reducing episodic cluster headaches: focus on galcanezumab","volume":"13","author":"L Pellesi","year":"2020","journal-title":"J Pain Res"},{"issue":"24","key":"ref43","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"H C Detke","year":"2018","journal-title":"Neurology"},{"issue":"09","key":"ref44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial","volume":"75","author":"V L Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"M Ashina","year":"2020","journal-title":"Cephalalgia"},{"issue":"09","key":"ref46","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial","volume":"39","author":"D W Dodick","year":"2019","journal-title":"Cephalalgia"},{"issue":"13","key":"ref47","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"R B Lipton","year":"2020","journal-title":"Neurology"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-020-01186-3","article-title":"Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24\u2009weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study","volume":"21","author":"S Silberstein","year":"2020","journal-title":"J Headache Pain"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/ane.13603","article-title":"Eptinezumab for migraine prevention in patients 50 years or older","volume":"145","author":"V Martin","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"23","key":"ref50","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial","volume":"325","author":"P K Winner","year":"2021","journal-title":"JAMA"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(20)32624-6","article-title":"Oral rimegepant for migraine prevention","volume":"397","author":"L Edvinsson","year":"2021","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"R Croop","year":"2021","journal-title":"Lancet"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40261-022-01130-0","article-title":"Atogepant for migraine prevention: a systematic review of efficacy and safety","volume":"42","author":"A Singh","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1007\/s10072-021-05547-x","article-title":"Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series","volume":"42","author":"T Toni","year":"2021","journal-title":"Neurol Sci"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/head.13843","article-title":"Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: Is there a rationale?","volume":"60","author":"L Pellesi","year":"2020","journal-title":"Headache"},{"issue":"08","key":"ref56","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/pm\/pnab093","article-title":"Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine","volume":"22","author":"F Cohen","year":"2021","journal-title":"Pain Med"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11916-022-01023-z","article-title":"Behavioral management of episodic migraine: maintaining a healthy consistent lifestyle","volume":"26","author":"E K Seng","year":"2022","journal-title":"Curr Pain Headache Rep"},{"issue":"01","key":"ref58","first-page":"8","article-title":"Early and long period follow-up results of low glycemic index diet for migraine prophylaxis","volume":"30","author":"G Evcili","year":"2018","journal-title":"Agri"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.numecd.2014.12.006","article-title":"Low-lipid diet reduces frequency and severity of acute migraine attacks","volume":"25","author":"L A Ferrara","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"04","key":"ref60","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/head.13507","article-title":"Headache triggers as surprise","volume":"59","author":"D P Turner","year":"2019","journal-title":"Headache"},{"issue":"21","key":"ref61","doi-asserted-by":"crossref","first-page":"e2203","DOI":"10.1212\/WNL.0000000000009473","article-title":"Effect of yoga as add-on therapy in migraine (CONTAIN): a randomized clinical trial","volume":"94","author":"A Kumar","year":"2020","journal-title":"Neurology"},{"issue":"07","key":"ref62","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/head.13313","article-title":"Cognitive-behavioral therapy for insomnia to reduce chronic migraine: a sequential Bayesian analysis","volume":"58","author":"T A Smitherman","year":"2018","journal-title":"Headache"},{"issue":"03","key":"ref63","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/PSY.0000000000000675","article-title":"Mindfulness training and physical health: mechanisms and outcomes","volume":"81","author":"J D Creswell","year":"2019","journal-title":"Psychosom Med"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000501425","article-title":"Is mindfulness-based stress reduction a promising and feasible intervention for patients suffering from migraine? A randomized controlled pilot trial","volume":"27","author":"K Simsh\u00e4user","year":"2020","journal-title":"Complement Med Res"},{"issue":"08","key":"ref65","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/j.pain.0000000000001860","article-title":"Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes","volume":"161","author":"D A Seminowicz","year":"2020","journal-title":"Pain"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/head.13194","article-title":"Headache education active-waiting directive: a program to enhance well-being during long referral wait times","volume":"58","author":"A M Lagman-Bartolome","year":"2018","journal-title":"Headache"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1129-2377-14-S1-P184","article-title":"Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly\u00ae device (PREMICE): a multi-centre, randomized, sham-controlled trial","volume":"14","author":"J Schoenen","year":"2013","journal-title":"J Headache Pain"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1177\/0333102418762525","article-title":"A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)","volume":"38","author":"A J Starling","year":"2018","journal-title":"Cephalalgia"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/bs.pbr.2020.06.009","article-title":"Update on noninvasive neuromodulation for migraine treatment - vagus nerve stimulation","volume":"255","author":"J Schoenen","year":"2020","journal-title":"Prog Brain Res"},{"issue":"12","key":"ref70","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1177\/0333102419876920","article-title":"Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial","volume":"39","author":"H C Diener","year":"2019","journal-title":"Cephalalgia"},{"issue":"09","key":"ref71","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1177\/0333102412446313","article-title":"Effects of repetitive transcranial magnetic stimulation on somatosensory evoked potentials and high frequency oscillations in migraine","volume":"32","author":"G Coppola","year":"2012","journal-title":"Cephalalgia"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/nu12010243","article-title":"The role of vitamin D in primary headache - from potential mechanism to treatment","volume":"12","author":"M Nowaczewska","year":"2020","journal-title":"Nutrients"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/head.13217","article-title":"Magnesium in migraine prophylaxis - Is there an evidence-based rationale? A systematic review","volume":"58","author":"A von Luckner","year":"2018","journal-title":"Headache"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1468-2982.1996.1604257.x","article-title":"Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study","volume":"16","author":"A Peikert","year":"1996","journal-title":"Cephalalgia"},{"issue":"17","key":"ref75","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0b013e3182535d0c","article-title":"Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"S Holland","year":"2012","journal-title":"Neurology"},{"issue":"09","key":"ref76","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1526-4610.2004.04170.x","article-title":"A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial","volume":"44","author":"M Maizels","year":"2004","journal-title":"Headache"},{"issue":"05","key":"ref77","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.mcna.2017.04.006","article-title":"Complementary and integrative medicine for neurologic conditions","volume":"101","author":"R E Wells","year":"2017","journal-title":"Med Clin North Am"},{"issue":"07","key":"ref78","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1468-2982.2002.00396.x","article-title":"The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis \u2013 a double-blind, multicentre, randomized placebo-controlled dose-response study","volume":"22","author":"V Pfaffenrath","year":"2002","journal-title":"Cephalalgia"},{"issue":"05","key":"ref79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0049-3848(87)90383-5","article-title":"An extract of feverfew inhibits interactions of human platelets with collagen substrates","volume":"48","author":"W L\u00f6sche","year":"1987","journal-title":"Thromb Res"},{"issue":"11","key":"ref80","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/1028415X.2019.1572940","article-title":"Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials","volume":"23","author":"M Parohan","year":"2020","journal-title":"Nutr Neurosci"},{"issue":"12","key":"ref81","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1212\/01.WNL.0000147290.68260.11","article-title":"Petasites hybridus root (butterbur) is an effective preventive treatment for migraine","volume":"63","author":"R B Lipton","year":"2004","journal-title":"Neurology"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","article-title":"Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study","volume":"47","author":"S Diamond","year":"2007","journal-title":"Headache"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1933-4366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T09:36:32Z","timestamp":1700991392000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1933-4366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":82,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,11,2]]},"published-print":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1933-4366","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"type":"print","value":"0271-8235"},{"type":"electronic","value":"1098-9021"}],"subject":[],"published-other":{"date-parts":[[2022,8,30]]},"published":{"date-parts":[[2022,8]]}}}